At a glance
Pioneering treatments to enhance and extend life
Cereno Scientific is an innovative biotech company developing novel therapies with disease-modifying potential and favorable safety and tolerability for people living with rare cardiovascular and pulmonary diseases.
Our science is grounded in years of research from Sahlgrenska Academy, University of Gothenburg, led by Professor Sverker Jern. Building on this strong scientific foundation, we are advancing a new therapeutic approach through epigenetic modulation to address the underlying mechanisms of disease — such as vascular remodeling, fibrosis, and inflammation.
Our three promising programs
Drug candidate
CS1
A pioneering HDAC inhibitor in development for pulmonary arterial hypertension (PAH). Completed a successful Phase IIa study, now preparing for Phase IIb with FDA Fast Track designation.
Drug candidate
CS014
A next-generation HDAC inhibitor with multimodal mechanism, first targeted for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Completed Phase I with favorable safety and tolerability, now advancing to Phase IIb.
Drug candidate
CS585
A novel prostacyclin (IP) receptor agonist, in preclinical development for rare thrombotic disorders, designed to prevent clot formation without increasing bleeding risk.
Global company with clear vision
We are headquartered in GoCo Health Innovation City in Gothenburg, Sweden, and with a U.S. subsidiary in Kendall Square, Boston. We are listed on Nasdaq First North Growth Market (ticker: CRNO B).
A vision for patients, a strategy for growth
We believe scientific excellence and responsibility go hand in hand. By combining breakthrough research, global partnerships, and a focus on patient benefit Cereno Scientific is shaping the next generation of cardiovascular medicine — one that treats disease at its core and delivers lasting value to both patients and shareholders.